Lipid Nanoparticle Raw Materials Market To Reach $329.2 Million By 2030

Lipid Nanoparticle Raw Material Market Growth & Trends

The global lipid nanoparticle raw materials market size is anticipated to reach USD 329.2 million by 2030 and it is projected to grow at a CAGR of 5.66% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising demand for drug-delivery systems, advancements in healthcare technologies, and the increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological disorder are expected to boost the market further. Government investment can have a significant impact on the lipid nanoparticle raw material market. As governments invest in research and development of new technologies, including lipid nanoparticles, the demand for raw materials used in their production can increase. For instance, in April 2022, Croda International Plc was awarded USD 20.8 million by the UK Government to increase the output of its plant in Leek that manufactures lipids used in COVID-19 vaccines.

Advancements in lipid nanoparticle (LNP) formulation techniques have led to the development of more efficient and stable lipid-based carriers for drug delivery. Techniques such as microfluidics, solvent evaporation, and self-assembly processes enable precise control over the size, morphology, and surface properties of LNP, enhancing their performance as drug delivery vehicles. Researchers have developed innovative encapsulation strategies to improve the loading capacity and release kinetics of active pharmaceutical ingredients in LNP. Techniques such as solid lipid nanoparticle (SLN) technology, nanoemulsions, and lipid-drug conjugation enable efficient encapsulation of hydrophobic and hydrophilic drugs, as well as nucleic acids like RNA and DNA, expanding the range of therapeutic molecules that can be delivered using LNP.

The development of COVID-19 vaccines utilizing LNP-based delivery systems for mRNA vaccines garnered significant attention and resources during the pandemic. This increased focus on vaccine delivery technologies has indirectly benefited the market by driving innovation and investment in LNP formulation and manufacturing capabilities. Regulatory agencies expedited the review and approval processes for COVID-19 therapeutics and vaccines, including those utilizing LNP technology. While this facilitated rapid market entry for COVID-19 treatments, it also underscored the need for streamlined regulatory pathways and standards for LNP -based products in other therapeutic areas, potentially shaping future regulatory frameworks and market dynamics.

The market faces several challenges, including Intellectual property rights related to LNP formulations, manufacturing processes, and raw material compositions can pose barriers to market entry for new entrants and limit competition. Navigating patent landscapes and securing licenses for proprietary technologies can be challenging for companies seeking to commercialize lipid nanoparticle-based products. Transitioning from laboratory-scale to commercial-scale production of lipid nanoparticle-based products presents challenges in maintaining product quality, optimizing production yields, and meeting demand. Scale-up challenges include process scalability, equipment validation, and supply chain logistics.

 Request a free sample copy or view report summary: Lipid Nanoparticle Raw Materials Market Report

Lipid Nanoparticle Raw Materials Market Report Highlights

• Based on application, the therapeutic segment led the market with the largest revenue share of 62.25% in 2023, owing to the increasing collaborations between research institutions and industry players for the drug development and growing government funding

• Based on product, the kits segment held the largest market share in 2023. On the other hand, reagents are expected to grow at a significant CAGR during the forecast period

• Based on disease indication, the infectious disease segment dominated the market and is expected to grow at the fastest CAGR during the forecast period

• Based on end-use, the pharmaceutical & biotechnology companies segment led the market with the largest revenue share of 57.87% in 2023. The academic & research institute segment is expected to grow at a fastest CAGR during the forecast period

• North America dominated the market with a revenue share of 40.34% in 2023, owing to factors such as the significant burden of infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Lipid Nanoparticle Raw Materials Market Segmentation

Grand View Research has segmented the global lipid nanoparticle raw materials market based on application, product, diseases indication, end-user, and region:

Lipid Nanoparticle Raw Materials Application Outlook (Revenue, USD Million, 2018 - 2030)

• Therapeutics

• Research

Lipid Nanoparticle Raw Materials Product Outlook (Revenue, USD Million, 2018 - 2030)

• Kits

  • Ionizable lipids

  • PEGylated lipids

  • Sterol lipids

  • Neutral phospholipids

• Reagents

• Others

Lipid Nanoparticle Raw Materials Diseases Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer

• Infectious Diseases

• Blood Diseases

• Others

Lipid Nanoparticle Raw Materials End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Others

Lipid Nanoparticle Raw Materials Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Lipid Nanoparticle Raw Materials Market

• Merck KGaA

• Echelon Biosciences

• BroadPharm

• Avanti Polar Lipids

• Tebubio

• CordenPharma International

• Creative Biolabs

• Biopharma PEG Scientific Inc.

• NOF AMERICA CORPORATION

• Polysciences, Inc.